Ocular Immunology and Inflammation · 2023 · 28 citations · 18 references
MedicineOphthalmologyPharmacologyOcular DiseaseOcular PharmacologyOphthalmic SurgeryDiabetic RetinopathyMacular DegenerationOcular Targeted DeliveryRetinal PharmacotherapyRetinal Vascular DiseaseUveal DiseaseAnti-vegf Ocular TherapyDrug-induced UveitisHypertensive RetinopathyMacular Edema TreatmentNeovascular Macular DegenerationUveitis PharmacotherapyVascular Endothelial Growth FactorVascular Endothelial Growth Factor Receptors
PURPOSE: Faricimab, a novel pharmaceutical agent targeting both angiopoietin-2 and vascular endothelial growth factor-A pathways, has gained approval for treating neovascular age-related macular degeneration and diabetic macular oedema. While clinical trials have demonstrated its favorable safety profile, this research presents two cases of hypertensive uveitis following intravitreal Faricimab injections. METHODS: Medical history, clinical findings and multimodal images were retrospectively collected. RESULTS: The patients experienced elevated intraocular pressure, mutton-fat keratic precipitates, anterior and posterior segment inflammation shortly after faricimab administration. CONCLUSIONS: These cases prompt further investigation into the potential risk of uveitis associated with faricimab and underscore the importance of continued monitoring and research to elucidate its real-world safety profile.
18
Pegaptanib for Neovascular Age-Related Macular Degeneration
Evangelos S. Gragoudas, Anthony P. Adamis, Emmett T. Cunningham et al. · New England Journal of Medicine · 2004 · 2.3K citations · Full text
The Lancet · 2022 · 686 citations · Full text
Lihteh Wu, María Ana Martinez-Castellanos, Hugo Quiroz–Mercado et al. · Graefe s Archive for Clinical and Experimental Ophthalmology · 2007 · 457 citations
Medicine, Ophthalmology, Surgery +16